octobre 22 2020

An IPO Alternative: Life Sciences Reverse Merger


Many companies are seeking alternatives to the traditional IPO, and considering merging into a SPAC, or a reverse merger. For life sciences companies, reverse merger transactions have become a popular alternative approach to going public. Merging into a public life sciences company that has cash on hand and has experienced a failed clinical program raises a number of legal considerations. During this session, we will discuss:

  • How this differs from a reverse merger into a shell;
  • Structuring alternatives;
  • Documentation, process and timeline;
  • Addressing board and employee matters;
  • Anticipating litigation; and
  • Concurrent or subsequent financing opportunities.

CLE is not available when viewing a recording of this program. In order to receive credit you must have attended the live webinar program.

Téléchargements de ressources

Compétences et Secteurs liés

Stay Up To Date With Our Insights

See how we use a multidisciplinary, integrated approach to meet our clients' needs.